Given the high expression of Glut1 on erythrocytes, red blood cell exchange transfusion—similar to sickle cell anemia—has been proposed, and is under study for the therapy of Glut1 patients (ClinicalTrials.gov Identifier NCT04137692, accessed on 20 April 2022). This evidence concerns the gene SLC2A1 and sickle cell disease.